Clinical trials: Migraine Disorders
Episodic Migraine
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- NCT05711394
- Testing
- Atogepant
- Where
- 98 sites in United States, Belgium and 14 more
- Volunteers
- 450 people
- Sponsor
- AbbVie
Migraine, Migraine With Aura
A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
Single-center, single-dose, open-label, 5-period crossover (in each part), pharmacokinetic and safety study.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT05337254
- Testing
- Dihydroergotamine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies…
- Trial name
- NCT06701526
- Testing
- Eptinezumab
- Where
- 21 sites in United States
- Volunteers
- 164 people
- Sponsor
- H. Lundbeck A/S
Migraine
Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults
This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month.
- Trial name
- NCT04845178
- Testing
- ABP-450
- Where
- 62 sites in United States, Australia and 1 more
- Volunteers
- 797 people
- Sponsor
- AEON Biopharma, Inc.
Migraine Headache
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks
This study evaluates the non-inferiority of Cefaliv® compared to Neosaldina® in the treatment of migraine attack in two hundred and sixteen adults of both sexes with age between eighteen and sixty five years old.
- Trial name
- NCT02706015
- Where
- Brazil
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Migraine
Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects
The purpose of this study is: To compare the single-dose pharmacokinetics (PK) of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet…
- Trial name
- NCT01507610
- Testing
- Sumatriptan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Optinose US Inc.
Migraine Disorders
The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine
This study was a randomized, parallel group, double-blind, placebo controlled design to compare the efficacy and tolerability of NP101 to a placebo iontophoretic transdermal patch.
- Trial name
- NP101-007 (NCT00724815)
- Testing
- NP101 - Sumatriptan iontophoretic transdermal patch
- Where
- 34 sites in United States
- Volunteers
- 530 people
- Sponsor
- NuPathe Inc.
Migraine
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
This study is an open label extension study, which means that the participants from the Lead-in Study 19140A (NCT04921384) can join this study, if they meet the study Eligibility Criteria, and continue to receive the study drug…
- Trial name
- NCT05064371
- Testing
- Eptinezumab
- Where
- 17 sites in Japan
- Volunteers
- 160 people
- Sponsor
- H. Lundbeck A/S
Migraine Disorders
Chronic Migraine Epidemiology and Outcomes Study
This is a population internet-based study to characterize migraine clinical course and impact on family.
- Trial name
- NCT01648530
- Testing
- No Treatment
- Volunteers
- 16,789 people
- Sponsor
- Allergan
Migraine
Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)
The purpose of this study is to test the effectiveness of an approved drug in the early treatment of migraine while the pain is still mild.
- Trial name
- NCT00092963
- Testing
- MK0462, rizatriptan benzoate / Duration of Treatment: 1day
- Volunteers
- 529 people
- Sponsor
- Organon and Co
Chronic Migraine, Headache
Adjunctive Treatment of Chronic Migraine Using an Oral Dental Device
Single blinding study comparing FDA cleared device for prevention of medically diagnosed migraine pain to placebo.
- Trial name
- NCT04871581
- Testing
- NTI-tss
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- ChairsideSplint.com
Migraine Disorders
Drug Use Investigation for IMIGRAN Tablet
The study is designed to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy of sumatriptan…
- Trial name
- NCT01376141
- Testing
- Sumatriptan
- Volunteers
- 3,571 people
- Sponsor
- GlaxoSmithKline
Migraine
A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents
The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) in treating acute migraine headaches in adolescents.
- Trial name
- NCT00210483
- Testing
- almotriptan malate
- Volunteers
- 866 people
- Sponsor
- Janssen-Ortho LLC
Migraine Disorders
Use Of GW274150 In The Prophylactic Treatment Of Migraine
Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO.
- Trial name
- NCT00242866
- Testing
- GW274150
- Where
- 62 sites in Belgium, Denmark and 7 more
- Volunteers
- 430 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute…
- Trial name
- Adelphi DSP (NCT06412965)
- Where
- United States
- Volunteers
- 528 people
- Sponsor
- Pfizer
Episodic Migraine
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.
- Trial name
- PROSPECT-1 (NCT05897320)
- Testing
- Eptinezumab
- Where
- 60 sites in United States, Argentina and 9 more
- Volunteers
- 315 people
- Sponsor
- H. Lundbeck A/S
Migraine
A Controlled Trial of Erenumab in Migraine Prevention
The purpose of this study was to assess the efficacy and safety of erenumab for prevention of migraine in Japanese adults with episodic migraine (EM) and chronic migraine (CM).
- Trial name
- NCT03812224
- Testing
- Erenumab
- Where
- 41 sites in Japan
- Volunteers
- 261 people
- Sponsor
- Amgen
Acute Migraine
DFN-02 Open Label Safety Study in Patients With Acute Migraine
A multi-center, open-label, safety study of DFN-02 for the Treatment of Acute Migraines
- Trial name
- NCT02279082
- Testing
- DFN-02
- Where
- 24 sites in United States
- Volunteers
- 167 people
- Sponsor
- Dr. Reddy's Laboratories Limited